Table 6 Per HPV type positive agreement between Roche Linear Array Genotyping Test (LA) and Nanopore
From: An economical Nanopore sequencing assay for human papillomavirus (HPV) genotyping
HPV Genotypes | Number of specimens | Positive agreement | |||||
|---|---|---|---|---|---|---|---|
Nanopore−/LA−/LA- | Nanopore +/LA- | Nanopore−/LA+ | Nanopore+/LA+ | Total | |||
High-risk | 16 | 183 | 0 | 1 | 7 | 191 | 87.5% |
18 | 190 | 0 | 0 | 1 | 191 | 100% | |
31 | 188 | 0 | 0 | 3 | 191 | 100% | |
33 | 189 | 0 | 0 | 2 | 191 | 100% | |
35 | 190 | 0 | 0 | 1 | 191 | 100% | |
39 | 185 | 0 | 1 | 5 | 191 | 83.33% | |
51 | 182 | 0 | 1 | 8 | 191 | 88.89% | |
52 | 165 | 3 | 2 | 21 | 191 | 80.77% | |
56 | 185 | 0 | 0 | 6 | 191 | 100% | |
58 | 184 | 0 | 0 | 7 | 191 | 100% | |
59 | 179 | 2 | 1 | 9 | 191 | 75% | |
66 | 182 | 1 | 0 | 8 | 191 | 88.89% | |
68 | 186 | 2 | 2 | 1 | 191 | 20% | |
Non-high risk | 6 | 190 | 0 | 0 | 1 | 191 | 100% |
11 | 189 | 0 | 0 | 2 | 191 | 100% | |
26 | 190 | 1 | 0 | 0 | 191 | 0% | |
40 | 187 | 2 | 0 | 2 | 191 | 50% | |
42 | 186 | 2 | 1 | 2 | 191 | 40% | |
53 | 181 | 3 | 0 | 7 | 191 | 70% | |
54 | 181 | 0 | 4 | 6 | 191 | 60% | |
55 | 186 | 0 | 0 | 5 | 191 | 100% | |
61 | 186 | 0 | 0 | 5 | 191 | 100% | |
62 | 174 | 2 | 2 | 13 | 191 | 76.47% | |
70 | 188 | 0 | 0 | 3 | 191 | 100% | |
71 | 189 | 0 | 2 | 0 | 191 | 0% | |
72 | 190 | 0 | 0 | 1 | 191 | 100% | |
73 | 190 | 0 | 0 | 1 | 191 | 100% | |
81 | 182 | 0 | 1 | 8 | 191 | 88.89% | |
82 | 189 | 0 | 0 | 2 | 191 | 100% | |
83 | 189 | 0 | 0 | 2 | 191 | 100% | |
84 | 183 | 0 | 5 | 3 | 191 | 37.5% | |
89 | 188 | 0 | 0 | 3 | 191 | 100% | |